This agreement aims to benefit from GlaxoSmithKline Healthcare’s expertise in the consumer healthcare sector and ensure the transfer of technology for consumer healthcare products to the Kingdom of Saudi Arabia. The agreement is for a period of 5 years, with total revenues estimated at 100 million Saudi riyals, which means increasing production capacity, and therefore it is expected to contribute to providing more job opportunities for Saudis.

Commenting on the agreement, the Group CEO said that this strategic cooperation will contribute to achieving the goal of localizing the pharmaceutical sector, as it aims to provide high-quality pharmaceutical and drug products to global pharmaceutical companies in the region, adding: “Our message is to be the best partner!”